Cargando…

The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients

Cutaneous melanoma is the third most common type of skin cancer in the world. The incidence of melanoma is increasing in most countries, however, mortality seems to be slowly decreasing. The treatment of advanced cutaneous melanoma changed radically since 2011. The new therapeutic modalities, such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kispál, Mihály, Jánváry, Levente Zsolt, Balatoni, Tímea, Gábor, Stelczer, Fedorcsák, Imre, Katalin, Bőcs, Kenessey, István, Liszkay, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492835/
https://www.ncbi.nlm.nih.gov/pubmed/36157171
http://dx.doi.org/10.3389/pore.2022.1610550
_version_ 1784793562775289856
author Kispál, Mihály
Jánváry, Levente Zsolt
Balatoni, Tímea
Gábor, Stelczer
Fedorcsák, Imre
Katalin, Bőcs
Kenessey, István
Liszkay, Gabriella
author_facet Kispál, Mihály
Jánváry, Levente Zsolt
Balatoni, Tímea
Gábor, Stelczer
Fedorcsák, Imre
Katalin, Bőcs
Kenessey, István
Liszkay, Gabriella
author_sort Kispál, Mihály
collection PubMed
description Cutaneous melanoma is the third most common type of skin cancer in the world. The incidence of melanoma is increasing in most countries, however, mortality seems to be slowly decreasing. The treatment of advanced cutaneous melanoma changed radically since 2011. The new therapeutic modalities, such as immuno- and targeted therapies give a chance to successfully reach more prolonged progression-free survival (PFS) and overall survival (OS) in patients with metastatic melanoma. Despite the great therapeutic benefit, most patients eventually develop resistance to these therapies, and the disease will progress. In some cases oligoprogression develops. In those cases local therapy, such as stereotactic radiotherapy can make it possible to continue the previously applied effective medical treatment for the benefit of patients. In our study of a total of 30 patients—20 of them received pre-treatment with systemic medical therapy—received stereotactic radiotherapy using various systems, in the National Institute of Oncology, Hungary, Budapest. We managed to prolong the systemic therapy for 12.5 months median period with the assistance of CyberKnife technique. Therapy related adverse events were mostly tolerable with only 3% of Grade 3 toxicity. We concluded that stereotactic radiotherapy and stereotactic radiosurgery, are safe, and effective therapeutic modalities for regional tumor control in cases of oligoprogression.
format Online
Article
Text
id pubmed-9492835
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94928352022-09-23 The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients Kispál, Mihály Jánváry, Levente Zsolt Balatoni, Tímea Gábor, Stelczer Fedorcsák, Imre Katalin, Bőcs Kenessey, István Liszkay, Gabriella Pathol Oncol Res Pathology and Oncology Archive Cutaneous melanoma is the third most common type of skin cancer in the world. The incidence of melanoma is increasing in most countries, however, mortality seems to be slowly decreasing. The treatment of advanced cutaneous melanoma changed radically since 2011. The new therapeutic modalities, such as immuno- and targeted therapies give a chance to successfully reach more prolonged progression-free survival (PFS) and overall survival (OS) in patients with metastatic melanoma. Despite the great therapeutic benefit, most patients eventually develop resistance to these therapies, and the disease will progress. In some cases oligoprogression develops. In those cases local therapy, such as stereotactic radiotherapy can make it possible to continue the previously applied effective medical treatment for the benefit of patients. In our study of a total of 30 patients—20 of them received pre-treatment with systemic medical therapy—received stereotactic radiotherapy using various systems, in the National Institute of Oncology, Hungary, Budapest. We managed to prolong the systemic therapy for 12.5 months median period with the assistance of CyberKnife technique. Therapy related adverse events were mostly tolerable with only 3% of Grade 3 toxicity. We concluded that stereotactic radiotherapy and stereotactic radiosurgery, are safe, and effective therapeutic modalities for regional tumor control in cases of oligoprogression. Frontiers Media S.A. 2022-09-08 /pmc/articles/PMC9492835/ /pubmed/36157171 http://dx.doi.org/10.3389/pore.2022.1610550 Text en Copyright © 2022 Kispál, Jánváry, Balatoni, Gábor, Fedorcsák, Katalin, Kenessey and Liszkay. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pathology and Oncology Archive
Kispál, Mihály
Jánváry, Levente Zsolt
Balatoni, Tímea
Gábor, Stelczer
Fedorcsák, Imre
Katalin, Bőcs
Kenessey, István
Liszkay, Gabriella
The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients
title The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients
title_full The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients
title_fullStr The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients
title_full_unstemmed The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients
title_short The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients
title_sort role of stereotactic radiotherapy in the management of melanoma, a retrospective single institute preliminary study of 30 patients
topic Pathology and Oncology Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492835/
https://www.ncbi.nlm.nih.gov/pubmed/36157171
http://dx.doi.org/10.3389/pore.2022.1610550
work_keys_str_mv AT kispalmihaly theroleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT janvaryleventezsolt theroleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT balatonitimea theroleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT gaborstelczer theroleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT fedorcsakimre theroleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT katalinbocs theroleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT kenesseyistvan theroleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT liszkaygabriella theroleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT kispalmihaly roleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT janvaryleventezsolt roleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT balatonitimea roleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT gaborstelczer roleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT fedorcsakimre roleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT katalinbocs roleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT kenesseyistvan roleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients
AT liszkaygabriella roleofstereotacticradiotherapyinthemanagementofmelanomaaretrospectivesingleinstitutepreliminarystudyof30patients